SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced an expanded suite of solutions under SOPHiA DDM for Liquid Biopsy. The range of solutions, including MSK-ACCESS powered with SOPHiA DDM and custom solutions, will help progress oncology research and tumour mutation profiling. The rollout of SOPHiA GENETICS’ liquid biopsy capabilities demonstrates the company’s commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes.
For a sizeable number of cases, genomic testing of tumour tissue is not feasible due to either insufficient tissue material, low quality of the obtained tissue or the invasiveness of the procedure. Liquid biopsy testing offers an alternative to solid tumour testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumour DNA (ctDNA). Isolating these DNA samples from a simple blood draw can help guide clinical decisions in a manner that is faster and less invasive, expedite results for researchers and clinicians, and simplify monitoring. SOPHiA GENETICS’ liquid biopsy offering will help users enhance tumour profiling with advanced cfDNA analysis and a streamlined DNA-only NGS workflow, allowing users to go from extracted cfDNA into a comprehensive report in an efficient timeframe. SOPHiA DDM for Liquid Biopsy features SOPHiA GENETICS’ proprietary unique molecular identifier technology (CUMIN) that is designed to transform the way labs analyse cell-free DNA samples with exceptional performance and reliable results.
“Our goal at SOPHiA GENETICS is to increase the use of data-driven medicine around the world and decrease health inequities by making resources more accessible to all,” said Philippe Menu, MD, PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. “Liquid biopsy is a sophisticated testing capability that can help expedite clinical decisions and planning. It is inherently cheaper and faster than traditional biopsy methods and is an excellent tool for labs and health systems to have at their disposal. We feel strongly that increased use of liquid biopsy will help advance oncology care and we are excited to help our customers implement this offering.”
The SOPHiA GENETICS liquid biopsy solutions incorporate the company’s proprietary algorithms and advanced genomic analysis, made possible with Artificial Intelligence (AI), to provide customers with expedited and streamlined insights that increase the ability of clinician researchers to practice precision medicine. Additionally, the SOPHiA GENETICS solutions allow customers to retain full ownership of their databases and obtain reproducible data that can help accelerate future work.Click below to share this article